Summary

The global vaccine adjuvants market is projected to surpass USD 0.96 billion in 2029 from USD 0.70 billion in 2024, with a significant CAGR of 6.5%. Innovations in adjuvants, such as toll-like receptor agonists, emulsions, and saponin-based compounds, increased immunization programs in regions like Asia-Pacific, Latin America, and Africa, and rising demand for veterinary vaccines are some of the factors projecting growth of the vaccine adjuvants market.
“The emulsion-based adjuvants segment accounted for the highest share in 2023.”
On the basis of product, the vaccine adjuvant market is segmented into emulsion-based adjuvants, pathogen components, saponin-based adjuvants, particulate-based adjuvants and other products. Emulsion-based adjuvants accounted for the dominant share due to their effectiveness in enhancing immune responses and diversified applications in various vaccine types such as infectious diseases, cancer, and others. The pathogen components segment is likely to grow at a significant CAGR owing to advancements in vaccine technology and increased demand for more targeted, effective vaccines.
“ Organic adjuvant type dominated the market in 2023”
The adjuvant type segment is divided into organic and inorganic adjuvants. Organic adjuvants dominated the market in 2023. The factors attributable to their dominance are their versatility in various vaccine platforms (including mRNA and DNA vaccines) and their ability to enhance the immune response in both human and veterinary vaccines. Inorganic adjuvants are anticipated to grow at a significant CAGR owing to various factors such as safety profiles, efficacy, cost-effectiveness, and broad application across both human and veterinary vaccines.
“ Infectious diseases segment held dominant share”
On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and other diseases. The infectious diseases segment dominated the market owing to the increasing prevalence of infectious diseases, the rise in immunization programs across the globe, and the rise in research & development funding. The cancer segment is likely to grow at a significant CAGR owing to the increased adoption of TLR agonists, oil-in-water emulsions, and cytokines in cancer vaccine development and the shift towards personalized vaccines.
“North America: the largest share of the vaccine adjuvants market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the vaccine adjuvants market in 2023 and is estimated to continue dominance during the forecast period. The region's dominance is driven by advanced healthcare infrastructure, strong research and development activities, and the rising prevalence of infectious diseases and cancer. Furthermore, strong research & development for novel vaccine adjuvants and the presence of key market players in the region are some of the major factors projecting the growth of the market in the region.



In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the vaccine adjuvants market.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tire 1 - 45%, Tire 2 - 35%, andTire 3 - 20%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
GSK Plc (UK), Seppic (France), Croda International Plc (UK), SPI Pharma (UK), Phibro Animal Health Corporation (US), Agenus Inc. (US), Dynavax Technologies Corporation (US)are some of the major players operating in the vaccine adjuvants market.

Research Coverage:
This research report categorizes the vaccine adjuvants market product (driven by advanced healthcare infrastructure, strong research and development initiatives, and high cancer prevalence), adjuvant type (organic and inorganic), disease tye (infectious diseases, cancer, and others), application (commercial & research), vaccine type (human and veterinary), route of administration ( intramuscular, subcutaneous and other route of administration) nd region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the vaccine adjuvants market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the vaccine adjuvants market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the vaccine adjuvants and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (rising demand for vaccines and expanding government immunization programs, technological advancements & development of novel adjuvants, increasing livestock production and rising incidence of animal diseases, increased investment in research & development, and higher number of vaccines under pipeline), restraints (cost implications of vaccine adjuvant development and side effects and toxicity of adjuvants), opportunities (personalized and combination vaccines, increased investment in R&D plant-based vaccines and growth in companion animals market) and Challenges (concerns regarding animal-sourced vaccine adjuvants ) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on upcoming technologies in vaccine adjuvants manufacturing, research and development activities, and new product launches in the vaccine adjuvants market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the vaccine adjuvants market
• Competitive Assessment: GSK Plc (UK), Sepppic (France), Croda International Plc (UK), SPI Pharma (UK) among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 35
1.3.1 MARKETS COVERED & REGIONAL SCOPE 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 36
1.4 CURRENCY CONSIDERED 37
1.5 STAKEHOLDERS 37
1.6 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.1.1 SECONDARY DATA 40
2.1.2 PRIMARY DATA 40
2.2 MARKET ESTIMATION METHODOLOGY 42
2.2.1 MARKET ESTIMATION 42
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 44
2.2.3 TOP-DOWN APPROACH 44
2.3 MARKET GROWTH RATE PROJECTIONS 46
2.4 DATA TRIANGULATION 48
2.5 RESEARCH ASSUMPTIONS 49
2.6 RESEARCH LIMITATIONS 50
2.7 RISK ANALYSIS 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 56
4.1 VACCINE ADJUVANTS MARKET OVERVIEW 56
4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2023) 57
4.3 VACCINE ADJUVANTS MARKET SHARE, BY VACCINE TYPE, 2024 VS. 2029 58
4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Rising demand for vaccines and expanding government immunization programs 61
5.2.1.2 Technological advancements and development of novel adjuvants 62
5.2.1.3 Increasing livestock production and rising incidence of animal diseases 62
5.2.1.4 Increased investments in research & development and high number of vaccine adjuvants under pipeline 63
5.2.2 RESTRAINTS 63
5.2.2.1 Cost implications of vaccine adjuvant development 63
5.2.2.2 Side effects and toxicity of adjuvants 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Personalized and combination vaccines 64
5.2.3.2 Increased investments in R&D of plant-based vaccines 65
5.2.3.3 Growth in companion animals market 65
5.2.4 CHALLENGES 65
5.2.4.1 Concerns regarding animal-sourced vaccine adjuvants 65
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 66
5.4 PRICING ANALYSIS 66
5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022–2024 67
5.4.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2024 68
5.5 SUPPLY CHAIN ANALYSIS 69
5.6 VALUE CHAIN ANALYSIS 70
5.7 ECOSYSTEM ANALYSIS 72
5.7.1 VACCINE ADJUVANTS MARKET: RAW MATERIAL SUPPLIERS 73
5.7.2 VACCINE ADJUVANTS MARKET: PRODUCT MANUFACTURERS 73
5.7.3 VACCINE ADJUVANTS MARKET: END USERS 73
5.7.4 VACCINE ADJUVANTS MARKET: REGULATORY BODIES 74
5.8 TECHNOLOGY ANALYSIS 75
5.8.1 KEY TECHNOLOGIES 75
5.8.1.1 Toll-like receptor (TLR) agonists 75
5.8.1.2 Emulsion-based adjuvants 75
5.8.2 COMPLEMENTARY TECHNOLOGIES 76
5.8.2.1 Artificial intelligence (AI) and machine learning (ML) 76
5.8.3 ADJACENT TECHNOLOGIES 76
5.8.3.1 Nanotechnology in vaccine delivery 76
5.9 PATENT ANALYSIS 77
5.10 KEY CONFERENCES & EVENTS, 2024–2025 78
5.11 REGULATORY ANALYSIS 79
5.11.1 REGULATORY LANDSCAPE 79
5.11.1.1 North America 79
5.11.1.1.1 US 79
5.11.1.1.2 Canada 79
5.11.1.2 Europe 79
5.11.1.3 Asia Pacific 79
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.12 INVESTMENT & FUNDING SCENARIO 83
5.13 PORTER’S FIVE FORCES ANALYSIS 84
5.13.1 THREAT OF NEW ENTRANTS 85
5.13.2 THREAT OF SUBSTITUTES 85
5.13.3 BARGAINING POWER OF BUYERS 85
5.13.4 BARGAINING POWER OF SUPPLIERS 85
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 85
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 86
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 86
5.14.2 BUYING CRITERIA FOR END USERS 87
5.15 TRADE ANALYSIS 89
5.15.1 IMPORT DATA 89
5.15.2 EXPORT DATA 90
5.16 PIPELINE DATA FOR VACCINE ADJUVANTS 91
5.17 IMPACT OF AI/GENERATIVE AI ON VACCINE ADJUVANTS MARKET 92
6 VACCINE ADJUVANTS MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
6.2 EMULSION ADJUVANTS 95
6.2.1 EXTENSIVE USE OF EMULSION ADJUVANTS IN HUMAN VACCINES TO DRIVE GROWTH 95
6.3 PATHOGEN COMPONENTS 99
6.3.1 INCREASING NUMBER OF PROMINENT MARKET PLAYERS OFFERING BACTERIA-DERIVED ADJUVANTS TO DRIVE SEGMENTAL GROWTH 99
6.4 SAPONIN-BASED ADJUVANTS 103
6.4.1 INCREASING USE AND GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET GROWTH 103
6.5 PARTICULATE-BASED ADJUVANTS 107
6.5.1 GROWING POPULARITY OF MINERAL-BASED ADJUVANTS TO PROPEL MARKET 107
6.6 OTHER ADJUVANTS 111
7 VACCINE ADJUVANTS MARKET, BY ADJUVANT TYPE 116
7.1 INTRODUCTION 117
7.2 ORGANIC ADJUVANTS 117
7.2.1 GROWING DEMAND FOR VACCINES WITH HIGH EFFICACY TO BOOST MARKET 117
7.3 INORGANIC ADJUVANTS 121
7.3.1 INCREASING USE OF INORGANIC ADJUVANTS FOR VETERINARY VACCINE DEVELOPMENT TO SUPPORT MARKET GROWTH 121
 
8 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 126
8.1 INTRODUCTION 127
8.2 INTRAMUSCULAR 127
8.2.1 INTRAMUSCULAR ROUTE TO BE LARGEST AND FASTEST-GROWING MARKET SEGMENT DURING FORECAST PERIOD 127
8.3 SUBCUTANEOUS 131
8.3.1 WIDESPREAD USE OF SUBCUTANEOUS ROUTE OF ADMINISTRATION TO BOOST MARKET 131
8.4 OTHER ROUTES OF ADMINISTRATION 136
9 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 141
9.1 INTRODUCTION 142
9.2 INFECTIOUS DISEASES 142
9.2.1 INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 142
9.3 CANCER 147
9.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH 147
9.4 OTHER DISEASES 151
10 VACCINE ADJUVANTS MARKET, BY APPLICATION 156
10.1 INTRODUCTION 157
10.2 RESEARCH APPLICATIONS 157
10.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET 157
10.3 COMMERCIAL APPLICATIONS 161
10.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH 161
11 VACCINE ADJUVANTS MARKET, BY VACCINE TYPE 166
11.1 INTRODUCTION 167
11.2 HUMAN VACCINES 167
11.2.1 INFECTIOUS DISEASES 171
11.2.1.1 Rising prevalence of infectious diseases to drive market growth 171
11.2.2 THERAPEUTIC 175
11.2.2.1 Rising investments in development of therapeutic vaccines to boost market 175
11.3 VETERINARY VACCINES 179
11.3.1 COMPANION ANIMALS 183
11.3.1.1 Increasing pet ownership and rising focus on pet health and wellness to play key role in driving market growth 183
11.3.2 LIVESTOCK ANIMALS 187
11.3.2.1 Increasing demand for high-quality meat, dairy, and other animal products to aid growth 187
11.3.3 OTHER ANIMALS 191
12 VACCINE ADJUVANTS MARKET, BY REGION 196
12.1 INTRODUCTION 197
12.2 NORTH AMERICA 197
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 198
12.2.2 US 203
12.2.2.1 US to dominate North American market during forecast period 203
12.2.3 CANADA 207
12.2.3.1 Increasing government funding for vaccine research to drive market growth in Canada 207
12.3 EUROPE 211
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 214
12.3.2 GERMANY 215
12.3.2.1 Increasing investments by various key players and growing funding from government organizations to drive market 215
12.3.3 UK 219
12.3.3.1 Rising investments in vaccine development to boost market growth 219
12.3.4 FRANCE 223
12.3.4.1 Focus on new vaccine development to drive market growth 223
12.3.5 ITALY 227
12.3.5.1 Government initiatives for vaccine development to boost market growth 227
12.3.6 SPAIN 231
12.3.6.1 Increasing investments in vaccine development by government and private organizations to support market growth in Spain 231
12.3.7 REST OF EUROPE 234
12.4 ASIA PACIFIC 238
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 243
12.4.2 CHINA 244
12.4.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China 244
12.4.3 JAPAN 248
12.4.3.1 Government initiatives for vaccines to boost market 248
12.4.4 INDIA 252
12.4.4.1 Growth of biotechnology sector and development of new vaccines to support market growth in India 252
12.4.5 SOUTH KOREA 256
12.4.5.1 Strategic collaborations to expand both human and veterinary vaccine sectors in South Korea 256
12.4.6 AUSTRALIA 260
12.4.6.1 Government support and strategic alliances to drive market 260
12.4.7 REST OF ASIA PACIFIC 264
 
12.5 LATIN AMERICA 267
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 271
12.5.2 BRAZIL 272
12.5.2.1 Robust healthcare infrastructure and thriving livestock industry to support market growth 272
12.5.3 MEXICO 276
12.5.3.1 Government commitment to immunization programs to fuel growth 276
12.5.4 ARGENTINA 279
12.5.4.1 Growing pharmaceutical sector to drive growth in Argentina 279
12.5.5 REST OF LATIN AMERICA 283
12.6 MIDDLE EAST 286
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 286
12.6.2 GCC COUNTRIES 291
12.6.2.1 Saudi Arabia 294
12.6.2.1.1 Strategic emphasis on advancing vaccine development for both human and veterinary applications to fuel growth 294
12.6.2.2 United Arab Emirates (UAE) 298
12.6.2.2.1 Increasing focus on developing cutting-edge vaccine technologies to contribute to market growth 298
12.6.2.3 Rest of GCC countries 302
12.6.3 REST OF MIDDLE EAST 305
12.7 AFRICA 309
12.7.1 INCREASING INVESTMENTS IN VACCINE PRODUCTION FACILITIES TO SUPPORT MARKET GROWTH 309
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 309
13 COMPETITIVE LANDSCAPE 313
13.1 OVERVIEW 313
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023 313
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINE ADJUVANTS MARKET 314
13.3 REVENUE ANALYSIS, 2019–2023 315
13.4 MARKET SHARE ANALYSIS, 2023 316
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 318
13.5.1 STARS 319
13.5.2 EMERGING LEADERS 319
13.5.3 PERVASIVE PLAYERS 319
13.5.4 PARTICIPANTS 319
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 321
13.5.5.1 Company footprint 321
13.5.5.2 Product footprint 322
13.5.5.3 Application footprint 323
13.5.5.4 Region footprint 324
 
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 325
13.6.1 PROGRESSIVE COMPANIES 325
13.6.2 RESPONSIVE COMPANIES 325
13.6.3 DYNAMIC COMPANIES 325
13.6.4 STARTING BLOCKS 325
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 327
13.7 COMPANY VALUATION & FINANCIAL METRICS 328
13.7.1 FINANCIAL METRICS 328
13.7.2 COMPANY VALUATION 329
13.8 BRAND/PRODUCT COMPARISON 330
13.9 COMPETITIVE SCENARIO 331
13.9.1 PRODUCT LAUNCHES & APPROVALS 331
13.9.2 DEALS 331
13.9.3 EXPANSIONS 332
14 COMPANY PROFILES 333
14.1 KEY PLAYERS 333
14.1.1 GSK PLC 333
14.1.1.1 Business overview 333
14.1.1.2 Products offered 334
14.1.1.3 Recent developments 335
14.1.1.3.1 Deals 335
14.1.1.4 MnM view 335
14.1.1.4.1 Key strengths 335
14.1.1.4.2 Strategic choices 335
14.1.1.4.3 Weaknesses & competitive threats 336
14.1.2 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP) 337
14.1.2.1 Business overview 337
14.1.2.2 Products offered 338
14.1.2.3 Recent developments 339
14.1.2.3.1 Product launches 339
14.1.2.4 MnM view 340
14.1.2.4.1 Key strengths 340
14.1.2.4.2 Strategic choices 340
14.1.2.4.3 Weaknesses & competitive threats 340
14.1.3 CRODA INTERNATIONAL PLC 341
14.1.3.1 Business overview 341
14.1.3.2 Products offered 342
14.1.3.3 Recent developments 344
14.1.3.3.1 Deals 344
14.1.3.3.2 Expansions 345
 
14.1.3.4 MnM view 345
14.1.3.4.1 Key strengths 345
14.1.3.4.2 Strategic choices 345
14.1.3.4.3 Weaknesses & competitive threats 345
14.1.4 PHIBRO ANIMAL HEALTH CORPORATION 346
14.1.4.1 Business overview 346
14.1.4.2 Products offered 347
14.1.4.3 MnM view 348
14.1.4.3.1 Key strengths 348
14.1.4.3.2 Strategic choices 348
14.1.4.3.3 Weaknesses & competitive threats 348
14.1.5 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC) 349
14.1.5.1 Business overview 349
14.1.5.2 Products offered 351
14.1.5.3 MnM view 352
14.1.5.3.1 Key strengths 352
14.1.5.3.2 Strategic choices 352
14.1.5.3.3 Weaknesses & competitive threats 352
14.1.6 AGENUS INC. 353
14.1.6.1 Business overview 353
14.1.6.2 Products offered 354
14.1.6.3 Recent developments 354
14.1.6.3.1 Deals 354
14.1.7 NOVAVAX 355
14.1.7.1 Business overview 355
14.1.7.2 Products offered 356
14.1.8 AURORIUM (FORMERLY VERTELLUS) 357
14.1.8.1 Business overview 357
14.1.8.2 Products offered 357
14.1.8.3 Recent developments 358
14.1.8.3.1 Deals 358
14.1.9 DYNAVAX TECHNOLOGIES CORPORATION 359
14.1.9.1 Business overview 359
14.1.9.2 Products offered 360
14.1.9.3 Recent developments 361
14.1.9.3.1 Deals 361
14.1.10 MERCK KGAA 362
14.1.10.1 Business overview 362
14.1.10.2 Products offered 363
14.1.11 VAXINE PTY LTD. 364
14.1.11.1 Business overview 364
14.1.11.2 Products offered 364
14.1.12 HAWAII BIOTECH INC. 365
14.1.12.1 Business overview 365
14.1.12.2 Products offered 365
14.1.13 CSL LIMITED 366
14.1.13.1 Business overview 366
14.1.13.2 Products offered 367
14.1.14 OZ BIOSCIENCES 368
14.1.14.1 Business overview 368
14.1.14.2 Products offered 368
14.1.15 INVIVOGEN 370
14.1.15.1 Business overview 370
14.1.15.2 Products offered 371
14.2 OTHER PLAYERS 372
14.2.1 ALLERGY THERAPEUTICS 372
14.2.2 EUBIOLOGICS CO., LTD. 373
14.2.3 PACIFIC GENETECH LIMITED 374
14.2.4 RIBOXX GMBH 375
14.2.5 CAPTIVATE PHARMACEUTICALS LLC 376
14.2.6 CREATIVE DIAGNOSTICS 377
14.2.7 LITEVAX B.V. 378
14.2.8 MUKTA INDUSTRIES 379
14.2.9 ONCOVIR, INC. 380
14.2.10 TITERMAX USA, INC. 381
15 APPENDIX 382
15.1 DISCUSSION GUIDE 382
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 385
15.3 CUSTOMIZATION OPTIONS 387
15.4 RELATED REPORTS 387
15.5 AUTHOR DETAILS 388